Get the Stockscreener App
123.62
0.84%
-1.05
After Hours:
123.97
0.35
+0.28%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $123.62, with a volume of 6.96M.
It is down -0.84% in the last 24 hours and down -7.70% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$124.67
Open:
$123.84
24h Volume:
6.96M
Relative Volume:
1.21
Market Cap:
$215.16B
Revenue:
$43.84B
Net Income/Loss:
$13.90B
P/E Ratio:
15.51
EPS:
7.9725
Net Cash Flow:
$6.92B
1W Performance:
-2.55%
1M Performance:
-7.70%
6M Performance:
-5.45%
1Y Performance:
+9.04%
1-Day Range:
$122.61
$124.33
1-Week Range:
$122.61
$128.45
52-Week Range:
$110.86
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
123.62 | 216.79B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
100.72 | 149.02B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
356.24 | 141.06B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
90.70 | 116.68B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
82.45 | 49.01B | 5.88B | 1.34B | 577.90M | 2.3455 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Greater Midwest Financial Group LLC Buys 18,927 Shares of Abbott Laboratories $ABT - MarketBeat
Syverson Strege & Co Acquires 2,723 Shares of Abbott Laboratories $ABT - MarketBeat
Integrity Alliance LLC. Reduces Position in Abbott Laboratories $ABT - MarketBeat
Assetmark Inc. Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Sold by Spire Wealth Management - MarketBeat
Abbott Laboratories $ABT Shares Sold by Fisher Funds Management LTD - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Linscomb Wealth Inc. - MarketBeat
How Abbott Laboratories stock reacts to inflationary pressuresMarket Trend Review & Free Technical Confirmation Trade Alerts - newser.com
Technical signs of recovery in Abbott LaboratoriesWatch List & Trade Opportunity Analysis - newser.com
Is Abbott Laboratories a candidate for recovery playEarnings Performance Report & Weekly Sector Rotation Insights - newser.com
Looking at the Narrative for Abbott as Legal Wins and Device Growth Shift the Outlook - Yahoo Finance
Simon Quick Advisors LLC Buys 4,430 Shares of Abbott Laboratories $ABT - MarketBeat
Strs Ohio Raises Stake in Abbott Laboratories $ABT - MarketBeat
Amalgamated Bank Purchases 21,362 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Acquired by Atria Investments Inc - MarketBeat
Abbott Laboratories $ABT Shares Sold by Keybank National Association OH - MarketBeat
Hantz Financial Services Inc. Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Arkadios Wealth Advisors Has $3.78 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030 - Benzinga
Will a bounce in Abbott Laboratories offer an exitJuly 2025 Fed Impact & AI Based Buy and Sell Signals - newser.com
Is a relief rally coming for Abbott Laboratories holdersEarnings Risk Report & Free Community Supported Trade Ideas - newser.com
What is the fair value estimate for Abbott Laboratories (ABL) stock in 2025 - newser.com
Daymark Wealth Partners LLC Boosts Stock Holdings in Abbott Laboratories $ABT - MarketBeat
The Zacks Analyst Blog Highlights International Business Machines, Micron and Abbott - sharewise.com
Analyst IMS Investment Management Services Ltd. Decreases Stake in Abbott Laboratories $ABT - MarketBeat
Whalen Wealth Management Inc. Purchases New Position in Abbott Laboratories $ABT - MarketBeat
Jennison Associates LLC Grows Stock Position in Abbott Laboratories $ABT - MarketBeat
Will earnings trigger a reversal in Abbott Laboratories2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Patient sues Abbott after early heart valve replacement - Cardiovascular Business
Top Stock Reports for IBM, Micron & Abbott - Yahoo Finance
Abbott Trifecta Heart Valve Lawsuit Filed Over Device Failure, Removal - AboutLawsuits.com
New York Life Investment Management LLC Acquires 4,494 Shares of Abbott Laboratories $ABT - MarketBeat
Fairfield Financial Advisors LTD Sells 2,587 Shares of Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a buy in volatile markets2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - newser.com
Mizuho Markets Americas LLC Sells 8,006 Shares of Abbott Laboratories $ABT - MarketBeat
Biltmore Family Office LLC Has $3.97 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Howard Capital Management Inc. - MarketBeat
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $162 - 富途牛牛
Transcend Capital Advisors LLC Sells 3,073 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback - simplywall.st
Data supports Abbott Tendyne mitral valve replacement - MassDevice
First National Trust Co Reduces Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Is Abbott Laboratories stock a good choice for value investors2025 Geopolitical Influence & AI Forecasted Stock Moves - fcp.pa.gov.br
What makes Abbott Laboratories stock attractive to growth fundsM&A Rumor & Risk Adjusted Buy and Sell Alerts - Fundação Cultural do Pará
Will Abbott Laboratories (ABL) stock maintain strong growth2025 Market Overview & Community Consensus Stock Picks - newser.com
Abbott Laboratories, facing hundreds of lawsuits over safety of formula for premature babies, notches a win in federal court - Slipcase
Abbott’s New Study on Dydrogesterone: A Potential Game-Changer for Endometriosis Pain - TipRanks
Abbott Laboratories wins Illinois court case on NEC baby formula claims - Global Food Industry News
Is Abbott Laboratories (Common Stock) (ABL0) stock a buy for dividend portfoliosJuly 2025 Price Swings & Precise Buy Zone Identification - Fundação Cultural do Pará
Envestnet Asset Management Inc. Grows Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Oppenheimer Asset Management Inc. Decreases Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
3.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):